A seismic shift is underway in decentralized science as Bio Protocol's cryptocurrency surges approximately 90% following a groundbreaking AI-driven proposal for ADHD treatment on blockchain infrastructure. The catalyst: a $6.9 million funding round led by Maelstrom Fund, fueling the launch of Bio V2—a full-stack AI-native platform enabling onchain fundraising and autonomous AI co-scientists called BioAgents. This development, highlighted by an AI-generated peptide proposal targeting ADHD, signals DeSci may have finally found its market cycle, riding broader AI token momentum exemplified by assets like FET. The convergence of AI-native biotech funding with onchain execution frameworks suggests this narrative possesses substantial staying power beyond a single project spike.

Can BIO Crypto Token Sustain Its +40% Move Or Is a Reversion Incoming?

Bio Protocol’s 40% price spike arrived without a clean technical base, which cuts both ways. The move originated from a low-liquidity range, meaning the rally was fast and thin (classic low-float DeSci behavior).

Without verified exchange-level data, precise support and resistance levels are difficult to pin, but the structural setup follows a familiar pattern: explosive breakout on catalyst, followed by a consolidation or partial giveback before any sustained continuation.

BIO right now is sitting between hype and real utility, and the difference shows up in whether demand actually sticks after the spike, because if DeSci momentum keeps building and the platform starts delivering real results, that is where price can hold higher levels and turn this into a sustained move instead of a one-off event.

But that only works if interest stays tied to actual usage, not just narrative, and that is still being tested.

The risk is simple: if the price cannot hold above its pre-announcement level on a weekly close, it usually means the move was just hype-driven, and once that fades, the price tends to drift back down.

Also worth watching the broader space, because if related tokens start rolling over, that usually drags everything with it, and BIO would not be an exception.

LiquidChain Targets Early Mover Upside as DeSci Momentum Builds Across Chains

Bio Protocol’s spike demonstrates a pattern traders know well: the biggest returns in any emerging narrative go to the earliest positioned capital. By the time a 40% move is on the ticker, the asymmetric entry has already closed. That’s the uncomfortable arithmetic of late-stage entries — real catalyst, shrinking upside.

For traders looking ahead, LiquidChain is building the cross-chain infrastructure layer that emerging DeSci and DeFi applications will require, regardless of which individual token wins.

LiquidChain is a Layer 3 protocol that combines Bitcoin’s capital base, Ethereum’s DeFi depth, and Solana’s execution speed into a single, unified liquidity environment, without asset wrapping.

Its Deploy-Once Architecture means developers build once and access users across all three ecosystems simultaneously.

The LIQUID presale is currently priced at $0.0145, with $674,947.04 raised to date. Features include a Unified Liquidity Layer, Single-Step Execution, and Verifiable Settlement backed by trust-minimized state verification. Presales carry material risk, tokens may not list at a premium, and infrastructure plays require adoption to generate returns.